BJAB Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The BJAB cell line was established in 1973 from a 5-year-old African girl diagnosed with Epstein-Barr virus (EBV)-negative Burkitt’s lymphoma. This specific origin is crucial for research as it provides a distinct model for studying Burkitt’s lymphoma in the absence of EBV influence, which is common in many other lymphoma cell lines. The EBV-negative status of BJAB cells allows researchers to investigate the genetic and environmental factors contributing to lymphomagenesis without the confounding effects of the virus. BJAB cells are often used in oncological research, especially for exploring the pathophysiology of Burkitt's lymphoma, and for testing therapeutic strategies against it. The cell line displays many of the hallmark features of Burkitt’s lymphoma, including high proliferation rates and a characteristic immunophenotype. Its genetic stability and the robustness with which it can be cultured make it a valuable tool for in vitro experiments aimed at understanding lymphoma biology and assessing the efficacy of anti-cancer drugs. |
|---|---|
| Organism | Human |
| Tissue | Blood |
| Disease | Burkitt lymphoma |
| Applications | Analysis of B cell surface antigens, testing of cytotoxic drugs, mutational analysis, analysis of apoptotic mechanisms, HLA-typing |
| Synonyms | BJAb, BJA-B, BJAB-1, BJA-B1, BJA-B-1 |
Characteristics
| Age | 5 years |
|---|---|
| Gender | Female |
| Ethnicity | African |
| Morphology | Round cells |
| Cell type | B lymphoblast |
| Growth properties | Suspension |
Regulatory Data
| Citation | BJAB (Cytion catalog number 302006) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_5711 |
Biomolecular Data
| Antigen expression | CD10+, CD19+, CD20+, CD21(+), CD22+, CD23-, CD24-, CD32+, CD37+, CD38+, CD39-, CD40+, CD54+, CD72+, CD73-, CD75+, CD77+, CD81, CD82+, CD83+, CD84+, CD86+ |
|---|---|
| Karyotype | 46, hypodiploid |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 20% FBS, 10 mM HEPES |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Seeding density | 3 x 105 cells/ml |
| Fluid renewal | Every 3 to 5 days |
| Post-Thaw Recovery | Allow the cells to recover from the freezing process for at least 48 hours. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 302006-240125 | Certificate of Analysis | 23. May. 2025 | 302006 |
| 302006-201223 | Certificate of Analysis | 23. May. 2025 | 302006 |